Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Upgraded by Wells Fargo & Company

Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) from an equal weight rating to an overweight rating in a report published on Thursday morning, MarketBeat Ratings reports. The brokerage currently has $170.00 target price on the specialty pharmaceutical company’s stock, up from their prior target price of $130.00.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Needham & Company LLC reissued a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $140.00 to $175.00 in a research note on Thursday, December 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, TD Cowen lowered their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $180.33.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $133.96 on Thursday. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $138.27. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $8.10 billion, a PE ratio of 18.87, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. The firm’s 50 day simple moving average is $123.47 and its 200 day simple moving average is $117.22.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now owns 427,025 shares in the company, valued at approximately $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 5,053 shares of company stock worth $617,442 in the last ninety days. 4.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals in the 4th quarter worth $25,000. Quadrant Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the period. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at approximately $28,000. Allianz SE purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $29,000. Finally, Jones Financial Companies Lllp grew its position in shares of Jazz Pharmaceuticals by 75.1% in the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.